Dylan Wallace | Director of Business Development
Ryght, Inc.

Dylan Wallace got his start in clinical operations at PPD before spending three years at IQVIA and IQVIA Biotech, working directly with biotech sponsors navigating the site selection process. He saw firsthand where the bottlenecks live and what they actually cost a study. Today he leads Business Development at Ryght AI. The platform helps sponsors and CROs identify and rank sites using a composite scoring algorithm built on over 60 metrics, including site activation speed, disease prevalence, competing study load, historical enrollment performance, FDA violation history, and sponsor preference patterns. Sites are stack ranked against a protocol in under 60 seconds, and country-level scoring rolls up from the site data so teams know where to focus before outreach even begins. From there, Ryght surfaces validated investigator contacts in real time, pulling from sources like PubMed, NPI registries, and site websites with a 98% accuracy rate. Feasibility questionnaires go out through the same platform, with response tracking, dynamic follow-up logic, and a real-time dashboard that gives sponsors and CROs full visibility into site engagement as it progresses. Dylan also manages Ryght's strategic partnership with Microsoft, with the platform built on Azure and SOC 2 compliant, and owns the full sales cycle across the pharma, biotech, and CRO landscape. At Biotech X, he's walking through where site selection is genuinely breaking down for sponsors today and what closing that gap looks like in practice.